BUY

NOMURA

NOMURA STRUCTURED FINANCE SERVICES PRIVATE LIMITED, INDIA

RESULTS FIRST LOOK

Lupin reported 2QFY2 revenues 2% ahead of our estimates. Adjusted for a forex loss of INR 80mn, EBITDA was broadly in-line with our estimates. Net profit was subdued due to higher-than-expected tax rate which was a result of the Medicis milestone being booked in India. US and India remain key growth drivers. US growth is expected to be driven by OC launches and other low-competition products. Management guided to growth in domestic formulations at >20% y-y. At 18x FY13 the stock trades at a discount to front-line Indian generic companies. Maintain BUY.

Price target: 570.0 INR	Price (09 Nov 2011): 474.55 INR		
Research analyst: Saion Mukherjee	+91 22 4037 4184	saion.mukherjee@nomura.com	
Research analyst: Aditya Khemka	+91 22 4037 4197	aditya.khemka@nomura.com	
Publish Date: 10 Nov 2011			

US, India remain key drivers

٠	Earnings vs. our Forecast:	IN LINE
---	----------------------------	---------

Likely Impact:

٠	Earnings Estimates:	NO CHANGE
•	Dividend Estimates:	NO CHANGE
•	Price Target:	NO CHANGE
•	Long-term View:	CONFIRMED

Fig 1: Revenue mix review

(INR mn)	2QFY12	2QFY11	Y-o-Y	1QFY12	Q-o-Q	2QFY12E	vs. Nom.
Advanced market formulations	7,760	6,728	15%	7,013	11%	7,434	4%
US - branded business	1,449	1,217	19%	1,479	-2%	1,272	14%
US - generic	4,070	3,575	14%	3,451	18%	3,728	9%
US	5,519	4,792	15%	4,930	12%	5,000	10%
Europe	461	369	25%	417	11%	552	-17%
Japan	1,780	1,567	14%	1,666	7%	1,882	-5%
India formulations	5,120	4,191	22%	4,969	3%	5,115	0%
Other formulations	1,594	1,180	35%	1,348	18%	1,533	4%
API	1,976	1,951	1%	2,102	-6%	2,146	-8%
Licensing Income	966					900	
Net sales	17,416	14,050	24%	15,432	13%	17,128	2%

Source: Company data, Nomura estimates

Fig 2: Income Statement review

(in INR mn)	2QFY12	YoY (%)	2QFY11	QoQ (%)	1QFY12	vs. Nom. Est.	2QFY12
Gross Sales	17,522	24%	14,142	13%	15,543	2%	17,242
Excise Duty	105	14%	92	-5%	111	-8%	114
Net Sales	17,417	24%	14,050	13%	15,432	2%	17,128
Other Operating income	307	6%	289	25%	246	2%	300
Total operating income	17,724	24%	14,339	13%	15,677	2%	17,428
Material costs	5,979	9%	5,494	-3%	6,169	-3%	6,162
Staff costs	2,276	19%	1,916	4%	2,193	-3%	2,356
Other expenditure	5,429	38%	3,943	24%	4,372	15%	4,732

Total Expenditure	13,684	21%	11,353	7%	12,734	3%	13,250
EBITDA	4,040	35%	2,986	37%	2,944	-3%	4,178
EBITDA margins	22.8%		20.8%		18.8%		24.0%
Other income	16	16%	14	37%	12		10
Interest	66	-24%	88	15%	58	11%	60
Depreciation	522	20%	435	11%	471	11%	470
РВТ	3,468	40%	2,478	43%	2,426	-5%	3,658
Тах	751	177%	271	162%	286	37%	549
Tax rate	21.6%		10.9%		11.8%		15.0%
MI + Share of associates	49	-14%	57	24%	39	22%	40
PAT	2,669	24%	2,150	27%	2,101	-13%	3,069
(% of Operating Income)							
Material costs	33.7%	-458bps	38.3%	-562bps	39.4%	-162bps	35.4%
Staff costs	12.8%	-52bps	13.4%	-114bps	14.0%	-68bps	13.5%
Other Expenditure	30.6%	313bps	27.5%	274bps	27.9%	348bps	27.2%
EBITDA Margin	22.8%	197bps	20.8%	402bps	18.8%	-117bps	24.0%

Source: Company data, Nomura estimates

Revenues ahead of estimates; US & India growth strong; target of US\$3bn revs by FY15 reiterated

Lupin reported 24% y-y growth in net sales for 2QFY12. The growth was led by US and India business which grew 15% and 22% y-y, respectively. Europe and Japan sales registered growth of 25% and 14% y-y. API business was flat y-y and came in 8% below our expectations. The management reiterated the aspiration of being a US\$3bn top line company by FY15.

US: Growth in US was led by the new product launches which contributed 75% of the total growth. Volume and price variations in older products contributed the remaining 25%.

The generics business grew 14% y-y. As per the management, the generics business grew 30% y-y excluding the pricing decline in generic Lotrel.

Lupin launched generic Fortamet (US\$80mn) at risk in Sep 2011 with 180 day exclusivity. Management said that 2 months of inventory was sold during 2QFY12. Following the initial launch, Lupin was injuncted on 12th Oct 2011 from selling the product and a court hearing is scheduled in early Dec 2011 to decide on the injunction.

Lupin also launched generic Femcon FE (US\$60mn) during the quarter and has garnered 16% market share as per the management. Further, the company expects to launch generic Nor QD (US\$50mn) and LoSeasonique (US\$30mn) during 3QFY12 for which it already has final approval. The oral contraceptive franchise is expected to reach peak sales in FY14. Lupin has a cost advantage compared with other players in the space, as it is the only company that is vertically integrated on the OC portfolio.

The company said that they expect to launch 5-6 products in the US over 2HFY12. Lupin has a pipeline of 99 ANDAs including 19 FTFs pending approval which include niche product filings like OCs and ophthalmology products.

The branded business grew 19% y-y primarily led by the strong performance of Suprax franchise. The recently launched **Suprax** tablets registered strong revenue growth of 52% y-y, while the suspension formulation grew 6% in volume terms. Revenues from Antara declined 3% y-y during the quarter. The management conceded that the fenofibrate market has been shrinking since the ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial results were announced and this has had an adverse impact on Antara. As per the results of the ACCORD trial, simvastatin when taken in combination with fenofibrate does not significantly reduce the risk of heart strokes in Type 2 diabetes patients when compared with similar patients taking simvastatin with a placebo. Lastly, Aerochamber also registered a significant decline in revenues.

Going forward, the **management does not expect generic competition in Suprax** for the next 12 months. Lupin received a response letter from the FDA regarding Suprax drops in Sep 2011. The management expects to file the response and hear back from the FDA by Jun 2012. Regarding Allernaze, the management suggested a launch in FY13. On inorganic growth strategy, the company is looking at opportunities in the pediatric, allergy and ENT (Ear, Nose and Throat) spaces.

- India: Revenues from domestic sales grew 22% y-y for the quarter. Lupin booked sales of INR 180mn from the Eli Lilly (LLY US) deal for two months during the quarter. The insulin franchise is expected to generate a quarterly run rate of INR 350-400mn as per the management. The management expects to continue to grow revenues at >20% y-y.
- **Europe, Japan and API:** Europe continued to grow strongly albeit on a lower base. Japan revenues grew 14% y-y and the management expects to maintain a 12% growth. The API business disappointed, as it came in flat y-y.

Margins disappoint; Revenue cost mismatch at the Indore SEZ, inflation in input costs, sales promotion expenditure put pressure on EBITDA margins

Including the US\$20mn licensing income from Medicis, **EBITDA margins came in at 22.8% vs. our expectation of 24% for the quarter**. Inflation in input costs, Indore SEZ capacity under utilization and lumpiness in sales promotion costs put downward pressure on margins, as per management. The management expects to increase EBITDA margins by 50-70 bps each year. This would be achieved by transferring manufacturing site for Japanese products to Indian facilities, scaling up utilization of Indore SEZ and increased traction in US from the recent launches, in our view.

R&D spend in the quarter came in at 7.9% of sales which is in line with the management guidance of 7-8% for FY12.

Tax rate was higher than anticipated, as the Medicis milestone of US\$20mn was booked in India and was taxed at 32%. Excluding the milestone tax, business tax rate was at 18%. Management guided to a FY tax rate of 16-17%.

LPC trades at 18x FY13 est EPS; Maintain BUY

We remain long-term positive on LPC's US product pipeline, execution track record and robust India growth. We believe potential catalysts include Fortamet injunction hearing in early December, potential Asacol (US\$700mn) authorised generic launch, OCs approvals and market share ramp up and Geodon (US\$1bn) launch in 4QFY12. At 18x our FY13 est EPS of INR26.3/sh, the stock trades at a discount to front-line Indian generic companies. Maintain BUY.

Valuation Methodology and Investment Risks: See below

Note: Ratings and Price Targets are as of the date of the most recently published report (<u>http://go.nomuranow.com/research/globalresearchportal</u>) rather than the date of this email.

Results First Look is the analyst's preliminary interpretation of the results announcement. Our recommendation and earnings estimates are not beingchanged in this report. Any formal changes to our recommendation or earnings estimates will be made in a subsequent report, which may differ from the preliminary views expressed in this report.

New force in Research: Global from east to west

Nomura Equity Research website: <u>http://go.nomuranow.com/research/globalresearchportal</u> Nomura Strategy website: <u>https://apps.nomuranow.com/EQS</u>

Analyst Certification

We, Saion Mukherjee and Aditya Khemka, hereby certify (1) that the views expressed in this Research report accurately reflect our personal views about any or all of the subject securities or issuers referred to in this Research report, (2) no part of our compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this Research report and (3) no part of our compensation is tied to any specific investment banking transactions performed by Nomura Securities International, Inc., Nomura International plc or any other Nomura Group company.

Issuer Specific Regulatory Disclosures


Mentioned companies

Issuer name	Ticker	Price	Price date	Stock rating	Disclosures
Lupin	LPC IN	474.55 INR	09 Nov 2011	Buy	

Previous Rating

Issuer name	Previous Rating	Date of change
Lupin	Not Rated	30 Jan 2009

Lupin (LPC IN) Rating and target price chart (three year history) 474.55 INR (09 Nov 2011) Buy



l	Date	Rating	Target price	Closing price
	11-Jan-2011		570.00	455.20
2	27-Aug-2010		417.00	372.50
2	28-May-2010		2087.00	364.60
(01-Feb-2010		1707.00	314.80
	16-Oct-2009		1506.00	255.92
2	23-Sep-2009		1251.00	212.91
(02-Jun-2009		1028.00	163.44
:	30-Jan-2009		919.00	113.98
:	30-Jan-2009	Buy		113.98

For explanation of ratings refer to the stock rating keys located after chart(s)

Valuation Methodology We value LPC at 23x one yr forward earnings to arrive at a target price of INR 570. The valuation multiple is in line with other front line generic companies.

Risks that may impede the achievement of the target price The key risks to our view are: a) slowdown or fall in branded generic revenues. Suprax and Antara are both likely to face generic competition over the next 4-5 years and need to be replaced over time.; b) appreciation in INR against export currencies; c) regulatory changes including price control in key markets like India and Japan.

Important Disclosures

Online availability of research and conflict-of-interest disclosures

Nomura research is available on <u>www.nomuranow.com</u>, Bloomberg, Capital IQ, Factset, MarkitHub, Reuters and ThomsonOne. Important disclosures may be read at <u>http://go.nomuranow.com/research/globalresearchportal/pages/disclosures/disclosures.aspx/</u> or requested from Nomura Securities International, Inc., on 1-877-865-5752. If you have any difficulties with the website, please email <u>grpsupport-eu@nomura.com</u> for help.

The analysts responsible for preparing this report have received compensation based upon various factors including the firm's total revenues, a portion of which is generated by Investment Banking activities. Unless otherwise noted, the non-US analysts listed at the front of this report are not registered/qualified as research analysts under FINRA/NYSE rules, may not be associated persons of NSI, and may not be subject to FINRA Rule 2711 and NYSE Rule 472 restrictions on communications with covered companies, public appearances, and trading securities held by a research analyst account.

Industry Specialists identified in some Nomura International plc research reports are employees within the Firm who are responsible for the sales and trading effort in the sector for which they have coverage. Industry Specialists do not contribute in any manner to the content of research reports in which their names appear. *Marketing Analysts* identified in some Nomura research reports are research analysts employed by Nomura International plc who are primarily responsible for marketing Nomura's Equity Research product in the sector for which they have coverage. Marketing Analysts may also contribute to research reports in which their names appears in which their names appear and publish research on their sector.

Distribution of ratings (Global)

The distribution of all ratings published by Nomura Global Equity Research is as follows:

49% have been assigned a Buy rating which, for purposes of mandatory disclosures, are classified as a Buy rating; 41% of companies with this rating are investment banking clients of the Nomura Group*.

41% have been assigned a Neutral rating which, for purposes of mandatory disclosures, is classified as a Hold rating; 50% of companies with this rating are investment banking clients of the Nomura Group*.

10% have been assigned a Reduce rating which, for purposes of mandatory disclosures, are classified as a Sell rating; 20% of companies with this rating are investment banking clients of the Nomura Group*.

As at 30 September 2011. *The Nomura Group as defined in the Disclaimer section at the end of this report.

Explanation of Nomura's equity research rating system in Europe, Middle East and Africa, US and Latin America The rating system is a relative system indicating expected performance against a specific benchmark identified for each individual stock. Analysts may also indicate absolute upside to target price defined as (fair value - current price)/current price, subject to limited management discretion. In most cases, the fair value will equal the analyst's assessment of the current intrinsic fair value of the stock using an appropriate valuation methodology such as discounted cash flow or multiple analysis, etc.

STOCKS

A rating of '**Buy'**, indicates that the analyst expects the stock to outperform the Benchmark over the next 12 months. A rating of '**Reutral'**, indicates that the analyst expects the stock to perform in line with the Benchmark over the next 12 months. A rating of '**Reuce**', indicates that the analyst expects the stock to underperform the Benchmark over the next 12 months. A rating of '**Suspended'**, indicates that the rating, target price and estimates have been suspended temporarily to comply with applicable regulations and/or firm policies in certain circumstances including, but not limited to, when Nomura is acting in an advisory capacity in a merger or strategic transaction involving the company.

Benchmarks are as follows: United States/Europe: Please see valuation methodologies for explanations of relevant benchmarks for stocks (accessible through the left hand side of the Nomura Disclosure web page: <u>http://go.nomuranow.com/research/globalresearchportal</u>);Global Emerging Markets (ex-Asia): MSCI Emerging Markets ex-Asia, unless otherwise stated in the valuation methodology.

SECTORS

A 'Bullish' stance, indicates that the analyst expects the sector to outperform the Benchmark during the next 12 months. A 'Neutral' stance, indicates that the analyst expects the sector to perform in line with the Benchmark during the next 12 months. A 'Bearish' stance, indicates that the analyst expects the sector to underperform the Benchmark during the next 12 months.

Benchmarks are as follows: United States: S&P 500; Europe: Dow Jones STOXX 600; Global Emerging Markets (ex-Asia): MSCI Emerging Markets ex-Asia. Explanation of Nomura's equity research rating system for Asian companies under coverage ex Japan published from 30 October 2008 and in Japan from 6 January 2009 STOCKS

Stock recommendations are based on absolute valuation upside (downside), which is defined as (Target Price - Current Price) / Current Price, subject to limited management discretion. In most cases, the Target Price will equal the analyst's 12-month intrinsic valuation of the stock, based on an appropriate valuation methodology such as discounted cash flow, multiple analysis, etc.

A '**Buy'** recommendation indicates that potential upside is 15% or more. A '**Neutral'** recommendation indicates that potential upside is less than 15% or downside is less than 5%. A '**Reduce'** recommendation indicates that potential downside is 5% or more. A rating of '**Suspended'** indicates that the rating and target price have been suspended temporarily to comply with applicable regulations and/or firm policies in certain circumstances including when Nomura is acting in an advisory capacity in a merger or strategic transaction involving the subject company.

Securities and/or companies that are labelled as 'Not rated' or shown as 'No rating' are not in regular research coverage of the Nomura entity identified in the top banner. Investors should not expect continuing or additional information from Nomura relating to such securities and/or companies.

SECTORS

A 'Bullish' rating means most stocks in the sector have (or the weighted average recommendation of the stocks under coverage is) a positive absolute recommendation. A 'Neutral' rating means most stocks in the sector have (or the weighted average recommendation of the stocks under coverage is) a neutral absolute recommendation. A 'Bearish' rating means most stocks in the sector have (or the weighted average recommendation of the stocks under coverage is) a neutral absolute recommendation. A 'Bearish' rating means most stocks in the sector have (or the weighted average recommendation of the stocks under coverage is) a neutral absolute recommendation.

Explanation of Nomura's equity research rating system in Japan published prior to 6 January 2009 STOCKS

A rating of '1' or '**Strong buy'**, indicates that the analyst expects the stock to outperform the Benchmark by 15% or more over the next six months. A rating of '2' or '**Buy'**, indicates that the analyst expects the stock to outperform the Benchmark by 5% or more but less than 15% over the next six months. A rating of '3' or '**Neutral'**, indicates that the analyst expects the stock to either outperform or underperform the Benchmark by less than 5% over the next six months. A rating of '4' or '**Reduce'**, indicates that the analyst expects the stock to underperform the Benchmark by 5% or more but less than 15% over the next six months. A rating of '4' or '**Reduce'**, indicates that the analyst expects the stock to underperform the Benchmark by 5% or more but less than 15% over the next six months. A rating of '5' or '**Sell'**, indicates that the analyst expects the stock to underperform the Benchmark by 15% or more over the next six months. Stocks labeled '**Not rated'** or shown as '**No rating'** are not in Nomura's regular research coverage. Nomura might not publish additional research reports concerning this company, and it undertakes no obligation to update the analysis, estimates, projections, conclusions or other information contained herein.

SECTORS

A 'Bullish' stance, indicates that the analyst expects the sector to outperform the Benchmark during the next six months. A 'Neutral' stance, indicates that the analyst expects the sector to perform in line with the Benchmark during the next six months. A 'Bearish' stance, indicates that the analyst expects the sector to underperform the Benchmark during the next six months.

Benchmarks are as follows: Japan: TOPIX; United States: S&P 500, MSCI World Technology Hardware & Equipment; Europe, by sector -Hardware/Semiconductors: FTSE W Europe IT Hardware; Telecoms: FTSE W Europe Business Services; Business Services: FTSE W Europe; Auto &

Components: FTSE W Europe Auto & Parts; Communications equipment: FTSE W Europe IT Hardware; Ecology Focus: Bloomberg World Energy Alternate Sources; Global Emerging Markets: MSCI Emerging Markets ex-Asia.

Target Price

A Target Price, if discussed, reflect in part the analyst's estimates for the company's earnings. The achievement of any target price may be impeded by general market and macroeconomic trends, and by other risks related to the company or the market, and may not occur if the company's earnings differ from estimates.

Disclaimers

This document contains material that has been prepared by the Nomura entity identified at the top or bottom of page 1 herein, if any, and/or, with the sole or joint contributions of one or more Nomura entities whose employees and their respective affiliations are specified on page 1 herein or identified elsewhere in the document. Affiliates and subsidiaries of Nomura Holdings, Inc. (collectively, the 'Nomura Group'), include: Nomura Securities Co., Ltd. ('NSC') Tokyo, Japan; Nomura International plc ('NIplc'), UK; Nomura Securities International, Inc. ('NSI'), New York, US; Nomura International (Hong Kong) Ltd. ('NIHK'), Hong Kong; Nomura Financial Investment (Korea) Co., Ltd. ('NFIK'), Korea (Information on Nomura analysts registered with the Korea Financial Investment Association ('KOFIA') can be found on the KOFIA Intranet at http://dis.kofia.or.kr); Nomura Singapore Ltd. ('NSL'), Singapore (Registration number 197201440E, regulated by the Monetary Authority of Singapore); Capital Nomura Securities Public Company Limited ('CNS'), Thailand; Nomura Australia Ltd. ('NAL'), Australia (ABN 48 003 032 513), regulated by the Australian Securities and Investment Commission ('ASIC') and holder of an Australian financial services licence number 246412; P.T. Nomura Indonesia ('PTNI'), Indonesia; Nomura Securities Malaysia Sdn. Bhd. ('NSM'), Malaysia; Nomura International (Hong Kong) Ltd., Taipei Branch ('NITB'), Taiwan; Nomura Financial Advisory and Securities (India) Private Limited ('NFASL'), Mumbai, India (Registered Address: Ceejay House, Level 11, Plot F, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai- 400 018, India; Tel: +91 22 4037 4037, Fax: +91 22 4037 4111; SEBI Registration No: BSE INB011299030, NSE INB231299034, INF231299034, INE 231299034, INE 23

This material is: (i) for your private information, and we are not soliciting any action based upon it; (ii) not to be construed as an offer to sell or a solicitation of an offer to buy any security in any jurisdiction where such offer or solicitation would be illegal; and (iii) based upon information from sources that we consider reliable, but has not been independently verified by Nomura Group.

Nomura Group does not warrant or represent that the document is accurate, complete, reliable, fit for any particular purpose or merchantable and does not accept liability for any act (or decision not to act) resulting from use of this document and related data. To the maximum extent permissible all warranties and other assurances by Nomura group are hereby excluded and Nomura Group shall have no liability for the use, misuse, or distribution of this information. Opinions or estimates expressed are current opinions as of the original publication date appearing on this material and the information, including the opinions and estimates contained herein, are subject to change without notice. Nomura Group is under no duty to update this document. Any comments or statements made herein are those of the author(s) and may differ from views held by other parties within Nomura Group. Clients should consider whether any advice or recommendation in this report is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. Nomura Group does not provide tax advice.

Nomura Group, and/or its officers, directors and employees, may, to the extent permitted by applicable law and/or regulation, deal as principal, agent, or otherwise, or have long or short positions in, or buy or sell, the securities, commodities or instruments, or options or other derivative instruments based thereon, of issuers or securities mentioned herein. Nomura Group companies may also act as market maker or liquidity provider (as defined within Financial Services Authority ('FSA') rules in the UK) in the financial instruments of the issuer. Where the activity of market maker is carried out in accordance with the definition given to it by specific laws and regulations of the US or other jurisdictions, this will be separately disclosed within the specific issuer disclosures. This document may contain information obtained from third parties, including ratings from credit ratings agencies such as Standard & Poor's. Reproduction and distribution of third party content in any form is prohibited except with the prior written permission of the related third party. Third party content providers or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Third party content providers give no express or implied warranties, including, but not limited to, any warranties of mechantability or fitness for a particular purpose or use. Third party content providers give no express shall not be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal

fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content, including ratings. Credit ratings are statements of opinions and are not statements of fact or recommendations to purchase hold or sell securities. They do not address the suitability of securities or the suitability of securities for investment purposes, and should not be relied on as investment advice.

Any MSCI sourced information in this document is the exclusive property of Morgan Stanley Capital International Inc. ('MSCI'). Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, re-disseminated or used to create any financial products, including any indices. This information is provided on an "as is" basis. The user assumes the entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI, Morgan Stanley Capital International and the MSCI indexes are services marks of MSCI and its affiliates.

Investors should consider this document as only a single factor in making their investment decision and, as such, the report should not be viewed as identifying or suggesting all risks, direct or indirect, that may be associated with any investment decision. Nomura Group produces a number of different types of research product including, among others, fundamental analysis, quantitative analysis and short term trading ideas; recommendations contained in one type of research product may differ from recommendations contained in other types of research product, whether as a result of differing time horizons, methodologies or otherwise. Nomura Group publishes research product in a number of different ways including the posting of product on Nomura Group portals and/or distribution directly to clients. Different groups of clients may receive different products and services from the research department depending on their individual requirements.

Figures presented herein may refer to past performance or simulations based on past performance which are not reliable indicators of future performance. Where the information contains an indication of future performance, such forecasts may not be a reliable indicator of future performance. Moreover, simulations are based on models and simplifying assumptions which may oversimplify and not reflect the future distribution of returns. Certain securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of, or income derived from, the investment.

The securities described herein may not have been registered under the US Securities Act of 1933 (the '1933 Act'), and, in such case, may not be offered or sold in the US or to US persons unless they have been registered under the 1933 Act, or except in compliance with an exemption from the registration requirements of the 1933 Act. Unless governing law permits otherwise, any transaction should be executed via a Nomura entity in your home jurisdiction. This document has been approved for distribution in the UK and European Economic Area as investment research by Nlplc, which is authorized and regulated by the FSA and is a member of the London Stock Exchange. It does not constitute a personal recommendation, as defined by the FSA, or take into account the particular investment objectives, financial situations, or needs of individual investors. It is intended only for investors who are 'eligible counterparties' or 'professional clients' as defined by the FSA, and may not, therefore, be redistributed to retail clients as defined by the FSA. This document has been approved for distribution in Australia by NAL, which is authorized and regulated in Australia by the ASIC. This document has also been approved for distribution in Malaysia by NSM. In Singapore, this document has been distributed by NSL. NSL accepts legal responsibility for the content of this document, where it concerns securities, futures and foreign exchange, issued by their foreign affiliates in respect of recipients who are not accredited, expert or institutional investors as defined by the Securities and Futures Act (Chapter 289). Recipients of this document in Singapore should contact NSL in respect of matters arising from, or in connection with, this document. Unless prohibited by the provisions of Regulation S of the 1933 Act, this material is distributed in the US, by NSI, a US-registered broker-dealer, which accepts responsibility for its contents in accordance with the provisions of Rule 15a-6, under the US Securities Exchange Act of 1934.

This document has not been approved for distribution in the Kingdom of Saudi Arabia ('Saudi Arabia') or to clients other than 'professional clients' in the United Arab Emirates ('UAE') by Nomura Saudi Arabia, NIplc or any other member of Nomura Group, as the case may be. Neither this document nor any copy thereof may be taken or transmitted or distributed, directly or indirectly, by any person other than those authorised to do so into Saudi Arabia or in the UAE or to any person located in Saudi Arabia or to clients other than 'professional clients' in the UAE. By accepting to receive this document, you represent that you are not located in Saudi Arabia or that you are a 'professional client' in the UAE and agree to comply with these restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of Saudi Arabia or the UAE.

No part of this material may be (i) copied, photocopied, or duplicated in any form, by any means; or (ii) redistributed without the prior written consent of a member of Nomura Group. Further information on any of the securities mentioned herein may be obtained upon request. If this document has been distributed by electronic transmission, such as e-mail, then such transmission cannot be guaranteed to be secure or error-free as information could be intercepted, corrupted, lost, destroyed, arrive late or incomplete, or contain viruses. The sender therefore does not accept liability for any errors or omissions in the contents of this document, which may arise as a result of electronic transmission. If verification is required, please request a hard-copy version.

Nomura Group manages conflicts with respect to the production of research through its compliance policies and procedures (including, but not limited to, Conflicts of Interest, Chinese Wall and Confidentiality policies) as well as through the maintenance of Chinese walls and employee training.

Additional information is available upon request. Disclosure information is available at the Nomura Disclosure web page: http://go.nomuranow.com/research/globalresearchportal/pages/disclosures/disclosures.aspx

Nomura Structured Finance Services Private Limited, India	Tel: 91 22 3053 2345
Nomura, 9th Flr, Hiranandani Business Park Powai, Mumbai – 400076, INDIA	Fax: 91 22 3053 2111

Caring for the environment: to receive only the electronic versions of our research, please contact your sales representative.